Record Annual Revenue and Guidance
Full-year 2025 revenue reached $1,100,000,000, up 17% year-over-year (organic +13%). Management guided 2026 revenue of $1,274,000,000 to $1,294,000,000 (midpoint $1,284,000,000), implying ~17% year-over-year growth with ~10% normalized organic growth.
Strong Q4 Revenue and Organic Growth
Q4 2025 revenue was $304,000,000, up 24% year-over-year and 12% organically. Both subscription and volume-based revenue contributed to growth.
Margin Expansion and Adjusted EBITDA Growth
Adjusted EBITDA for Q4 was $129,000,000 (margin ~43%), up 29% year-over-year. Full-year adjusted EBITDA was $462,000,000 (42% margin), up 21% year-over-year. 2026 adjusted EBITDA guidance midpoint $535,000,000 (approx. +16% YoY) targeting ~42% margin.
Record Bookings and Large Deal Activity
Company reported a record bookings quarter in Q4, including an elevated count of $1M+ bookings (15–20 each in Q3 and Q4, more than 2x the three-year quarterly average), supporting forward visibility despite multi-quarter ramp timelines.
Iodine Acquisition and Synergy Progress
Completed acquisition of Iodine: contributed $31,000,000 in Q4, added >1,000 hospitals/health systems with ~35% customer overlap. Integration is ahead of plan and management expects to realize >90% of committed $15,000,000 cost synergies in fiscal 2026 (~$14,000,000).
AI Performance and Adoption
Waystar Altitude AI prevented >$15,000,000,000 in denials in 2025, reduced appeal package generation time by 90%, drove double-digit increases in denial overturn rates, and launched agentic capabilities that cut documentation analysis by ~40%. About 50 solutions leverage AI and ~40% of revenue is driven by AI; ~30% of 2025 new bookings were AI-powered.
Strong Retention, NPS and Commercial Metrics
Net revenue retention (NRR) was 112% (last twelve months) with 97% gross revenue retention. Net promoter score exceeded 70. Clients with >$100k LTM revenue increased by 85 in Q4 to 1,391 (+16% YoY), and win rates improved above a historical ~80%.
Cash Flow, Leverage Improvement and Conversion
Unlevered free cash flow was $80,000,000 in Q4 and $365,000,000 for the full year, converting 79% of adjusted EBITDA to unlevered free cash flow. Net leverage was ~3.0x as of Dec 31, down ~0.5x since the Iodine close, with plan to run at or below 3.0x and delever ~1.0x per year.